蒙特罗莎:在市场放弃看涨论点之际的风险性逆势买入

· seekingalpha.com

蒙特罗莎治疗公司被评为风险性买入,原因是其5.8亿美元现金使其管线价值约2.15亿美元,并拥有MRT-6160和MRT-2359催化剂。

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...


More AI market news · Market heatmap · StrategyVerse · Quant Research · WOBR.AI